Predictive Value of CD44v6 and EGFR Expression in Neoadjuvant Chemotherapy Sensitivity of Stage Ⅱ-Ⅲ Cervical Cancer
Objective To explore the predictive value of the expression of CD44v6 and EGFR on the efficacy of neoadjuvant chemotherapy (NACT) in stageⅡ-Ⅲ cervical cancer. Methods A total of 53 patients with stageⅡ-Ⅲ cervical cancer diagnosed by pathology were selected. All patients received two cycles of paclit...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2022-09-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.22.0038 |
| _version_ | 1798020627687276544 |
|---|---|
| author | MAO Wanli RAN Li LI Jiehui LI Fenghu CHANG Jianying MU Junyu MEI Fan HU Lili DU Yanjun TIAN Xue QIN Yao YIN Shuishui |
| author_facet | MAO Wanli RAN Li LI Jiehui LI Fenghu CHANG Jianying MU Junyu MEI Fan HU Lili DU Yanjun TIAN Xue QIN Yao YIN Shuishui |
| author_sort | MAO Wanli |
| collection | DOAJ |
| description | Objective To explore the predictive value of the expression of CD44v6 and EGFR on the efficacy of neoadjuvant chemotherapy (NACT) in stageⅡ-Ⅲ cervical cancer. Methods A total of 53 patients with stageⅡ-Ⅲ cervical cancer diagnosed by pathology were selected. All patients received two cycles of paclitaxel+platinum NACT. The pathological tissue samples of cervical tumors before NACT treatment were collected. The expression of CD44v6 and EGFR were detected by the immunohistochemical SP method, and we analyzed their predictive value of NACT in stageⅡ-Ⅲ cervical cancer. Results Among the 53 patients, 38 were in the NACT effective group (CR+PR), and 15 were in the NACT ineffective group (SD+PD). The expression of CD44v6 in the ineffective group was significantly higher than that in the effective group (P < 0.05). The expression of CD44v6 was significantly different in patients with CR, PR, and SD (P < 0.05). The AUC of CD44v6 to NACT effect on stage Ⅱ-Ⅲ cervical cancer was 0.74 (P < 0.05). The patients in the high expression group of CD44v6 had worse efficacy in NACT than those in the low expression group of CD44v6 (P < 0.05). Pearson test showed that CD44v6 and EGFR expression were correlated (R=0.34, P < 0.05). Conclusion High expression of CD44v6 may reduce the efficacy of NACT in stageⅡ-Ⅲ cervical cancer, suggesting that the expression of CD44v6 has a certain predictive value and clinical significance in the efficacy of paclitaxel+platinum NACT on cervical cancer. Moreover, CD44v6 is positively correlated with EGFR expression. |
| first_indexed | 2024-04-11T17:00:34Z |
| format | Article |
| id | doaj.art-d7b696af0ac74345a0dbd20ec7b13be0 |
| institution | Directory Open Access Journal |
| issn | 1000-8578 |
| language | zho |
| last_indexed | 2024-04-11T17:00:34Z |
| publishDate | 2022-09-01 |
| publisher | Magazine House of Cancer Research on Prevention and Treatment |
| record_format | Article |
| series | Zhongliu Fangzhi Yanjiu |
| spelling | doaj.art-d7b696af0ac74345a0dbd20ec7b13be02022-12-22T04:13:10ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85782022-09-0149993794310.3971/j.issn.1000-8578.2022.22.00388578.2022.22.0038Predictive Value of CD44v6 and EGFR Expression in Neoadjuvant Chemotherapy Sensitivity of Stage Ⅱ-Ⅲ Cervical CancerMAO Wanli0RAN Li1LI Jiehui2LI Fenghu3CHANG Jianying4MU Junyu5MEI Fan6HU Lili7DU Yanjun8TIAN Xue9QIN Yao10YIN Shuishui11Department of Gynecological Oncology, Guizhou Medical University Cancer Hospital, Guiyang 550004, ChinaDepartment of Gynecological Oncology, Guizhou Medical University Cancer Hospital, Guiyang 550004, ChinaDepartment of Gynecological Oncology, Guizhou Medical University Cancer Hospital, Guiyang 550004, ChinaDepartment of Gynecological Oncology, Guizhou Medical University Cancer Hospital, Guiyang 550004, ChinaDepartment of Gynecological Oncology, Guizhou Medical University Cancer Hospital, Guiyang 550004, ChinaDepartment of Clinical Medical Oncology, Guizhou Medical University, Guiyang 550004, ChinaDepartment of Gynecological Oncology, Guizhou Medical University Cancer Hospital, Guiyang 550004, ChinaDepartment of Gynecological Oncology, Guizhou Medical University Cancer Hospital, Guiyang 550004, ChinaDepartment of Gynecological Oncology, Guizhou Medical University Cancer Hospital, Guiyang 550004, ChinaDepartment of Gynecological Oncology, Guizhou Medical University Cancer Hospital, Guiyang 550004, ChinaDepartment of Clinical Medical Oncology, Guizhou Medical University, Guiyang 550004, ChinaDepartment of Gynecological Oncology, Guizhou Medical University Cancer Hospital, Guiyang 550004, ChinaObjective To explore the predictive value of the expression of CD44v6 and EGFR on the efficacy of neoadjuvant chemotherapy (NACT) in stageⅡ-Ⅲ cervical cancer. Methods A total of 53 patients with stageⅡ-Ⅲ cervical cancer diagnosed by pathology were selected. All patients received two cycles of paclitaxel+platinum NACT. The pathological tissue samples of cervical tumors before NACT treatment were collected. The expression of CD44v6 and EGFR were detected by the immunohistochemical SP method, and we analyzed their predictive value of NACT in stageⅡ-Ⅲ cervical cancer. Results Among the 53 patients, 38 were in the NACT effective group (CR+PR), and 15 were in the NACT ineffective group (SD+PD). The expression of CD44v6 in the ineffective group was significantly higher than that in the effective group (P < 0.05). The expression of CD44v6 was significantly different in patients with CR, PR, and SD (P < 0.05). The AUC of CD44v6 to NACT effect on stage Ⅱ-Ⅲ cervical cancer was 0.74 (P < 0.05). The patients in the high expression group of CD44v6 had worse efficacy in NACT than those in the low expression group of CD44v6 (P < 0.05). Pearson test showed that CD44v6 and EGFR expression were correlated (R=0.34, P < 0.05). Conclusion High expression of CD44v6 may reduce the efficacy of NACT in stageⅡ-Ⅲ cervical cancer, suggesting that the expression of CD44v6 has a certain predictive value and clinical significance in the efficacy of paclitaxel+platinum NACT on cervical cancer. Moreover, CD44v6 is positively correlated with EGFR expression.http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.22.0038cervical cancerneoadjuvant chemotherapycd44v6egfr |
| spellingShingle | MAO Wanli RAN Li LI Jiehui LI Fenghu CHANG Jianying MU Junyu MEI Fan HU Lili DU Yanjun TIAN Xue QIN Yao YIN Shuishui Predictive Value of CD44v6 and EGFR Expression in Neoadjuvant Chemotherapy Sensitivity of Stage Ⅱ-Ⅲ Cervical Cancer Zhongliu Fangzhi Yanjiu cervical cancer neoadjuvant chemotherapy cd44v6 egfr |
| title | Predictive Value of CD44v6 and EGFR Expression in Neoadjuvant Chemotherapy Sensitivity of Stage Ⅱ-Ⅲ Cervical Cancer |
| title_full | Predictive Value of CD44v6 and EGFR Expression in Neoadjuvant Chemotherapy Sensitivity of Stage Ⅱ-Ⅲ Cervical Cancer |
| title_fullStr | Predictive Value of CD44v6 and EGFR Expression in Neoadjuvant Chemotherapy Sensitivity of Stage Ⅱ-Ⅲ Cervical Cancer |
| title_full_unstemmed | Predictive Value of CD44v6 and EGFR Expression in Neoadjuvant Chemotherapy Sensitivity of Stage Ⅱ-Ⅲ Cervical Cancer |
| title_short | Predictive Value of CD44v6 and EGFR Expression in Neoadjuvant Chemotherapy Sensitivity of Stage Ⅱ-Ⅲ Cervical Cancer |
| title_sort | predictive value of cd44v6 and egfr expression in neoadjuvant chemotherapy sensitivity of stage ii iii cervical cancer |
| topic | cervical cancer neoadjuvant chemotherapy cd44v6 egfr |
| url | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.22.0038 |
| work_keys_str_mv | AT maowanli predictivevalueofcd44v6andegfrexpressioninneoadjuvantchemotherapysensitivityofstageiiiiicervicalcancer AT ranli predictivevalueofcd44v6andegfrexpressioninneoadjuvantchemotherapysensitivityofstageiiiiicervicalcancer AT lijiehui predictivevalueofcd44v6andegfrexpressioninneoadjuvantchemotherapysensitivityofstageiiiiicervicalcancer AT lifenghu predictivevalueofcd44v6andegfrexpressioninneoadjuvantchemotherapysensitivityofstageiiiiicervicalcancer AT changjianying predictivevalueofcd44v6andegfrexpressioninneoadjuvantchemotherapysensitivityofstageiiiiicervicalcancer AT mujunyu predictivevalueofcd44v6andegfrexpressioninneoadjuvantchemotherapysensitivityofstageiiiiicervicalcancer AT meifan predictivevalueofcd44v6andegfrexpressioninneoadjuvantchemotherapysensitivityofstageiiiiicervicalcancer AT hulili predictivevalueofcd44v6andegfrexpressioninneoadjuvantchemotherapysensitivityofstageiiiiicervicalcancer AT duyanjun predictivevalueofcd44v6andegfrexpressioninneoadjuvantchemotherapysensitivityofstageiiiiicervicalcancer AT tianxue predictivevalueofcd44v6andegfrexpressioninneoadjuvantchemotherapysensitivityofstageiiiiicervicalcancer AT qinyao predictivevalueofcd44v6andegfrexpressioninneoadjuvantchemotherapysensitivityofstageiiiiicervicalcancer AT yinshuishui predictivevalueofcd44v6andegfrexpressioninneoadjuvantchemotherapysensitivityofstageiiiiicervicalcancer |